PRESS RELEASE published on 08/15/2025 at 15:21, 1 year 2 months ago enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF published on 08/06/2025 at 14:35, 1 year 2 months ago VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRIEF published on 08/06/2025 at 14:35, 1 year 2 months ago EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE published on 08/06/2025 at 14:30, 1 year 2 months ago Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF published on 08/04/2025 at 15:10, 1 year 3 months ago EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRIEF published on 08/04/2025 at 15:10, 1 year 3 months ago EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement. Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
PRESS RELEASE published on 08/04/2025 at 15:05, 1 year 3 months ago enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF published on 08/01/2025 at 14:05, 1 year 3 months ago EnVVeno Medical Q2 2025 Financial Report and Corporate Update EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRIEF published on 08/01/2025 at 14:05, 1 year 3 months ago Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025 EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
PRESS RELEASE published on 08/01/2025 at 14:00, 1 year 3 months ago enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress
Published on 11/05/2026 at 08:00, 16 minutes ago Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
Published on 11/04/2026 at 23:10, 9 hours 6 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 9 hours 16 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 10 hours 1 minute ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/05/2026 at 08:07, 8 minutes ago Leifheit AG publishes its Q3 2026 quarterly statement and accelerates the FOCUS performance program
Published on 11/05/2026 at 08:00, 15 minutes ago Ørsted delivers strong earnings with 19 % EBITDA growth, and offshore wind farms Borkum Riffgrund 3 in Germany and Revolution Wind in the US reach commercial operations
Published on 11/05/2026 at 08:00, 16 minutes ago Nine months of 2026: 11880 Solutions AG increases EBITDA and strengthens the foundation for future growth
Published on 11/05/2026 at 07:00, 1 hour 16 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 07:00, 1 hour 16 minutes ago Eurazeo’s European asset management platform continues to gain momentum, driven by sustained international fundraising
Published on 11/05/2026 at 07:00, 1 hour 16 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%